University of California Berkeley
seal E. O. Lawrence Berkeley National
Laboratory seal
Carcinogenic Potency Project

Bromate, potassium (CAS 7758-01-2)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
kid per thy kid kid no positive 9.82m 53.8

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
Male Female
kid no test 533n

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   kid = kidney. per = peritoneal cavity. thy = thyroid gland. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. n = No positive results in this species in the CPDB are statistically significant (p<.1).

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Bromate, potassium: All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.
Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.
See Guide to reading the plot for details on each field, using an example of one experiment.
See Help to improve readability, or to fit the plot onto the screen or a printed page.

Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

BROMATE, POTASSIUM 7758-01-2 828 H m syg wat 89w89 2318 0 15.0mg 30.0mg 60.0mg Takamura;srtu,32,43-46;1985 kid rct h * P<.2 + n.s.s. 0/20 0/20 1/20 4/20 2/20 liv nnd no dre P=1. n.s.s. 0/20 0/20 0/20 1/20 0/20 tba mix no dre P=1. n.s.s. 10/20 14/20 7/20 8/20 9/20 829 M f b6c wat 18m24 1789 0 75.0mg Kurokawa;enhp,69,221-235;1986 liv ade e 1.18gm * P<.05 n.s.s. 0/46 3/48 3/47 lun mix e 1.05gm * P<.2 n.s.s. 3/46 3/48 8/47 liv mix e 1.71gm * P<.4 n.s.s. 3/46 3/48 6/47 lun ade e 2.03gm * P<.3 n.s.s. 2/46 1/48 5/47 tba mix e * P<.2 n.s.s. 15/46 16/48 22/47 830 M m b6c wat 52w53 2348m 0 13.3mg 66.7mg DeAngelo;txpy,26,587-594;1998/pers.comm. kid tum ek no dre P=1. 3.79mg n.s.s. 0/7 0/7 0/7 0/6 831 M m b6c wat 78w78 2348n 0 13.3mg 66.7mg kid tum ek no dre P=1. 8.07mg n.s.s. 0/7 0/7 0/7 0/5 832 M m b6c wat 23m23 2348o : 0 13.3mg 66.7mg kid mix 53.8mg Z P<.008 + 20.4mg 0/40 5/38 (3/41 1/44) kid rcc 92.5mg Z P<.04 28.0mg n.s.s. 0/40 3/38 (1/41 0/44) 833 M f the eat 80w80 719 0 6.50mg 9.75mg Ginocchio;fctx,17,41-47;1979 liv hem e * P<.6 - 56.4mg n.s.s. 0/53 1/54 0/52 834 M m the eat 80w80 719 0 6.00mg 9.00mg liv tum e no dre P=1. - 21.3mg n.s.s. 0/35 0/46 0/53 tba mal e no dre P=1. - 63.9mg n.s.s. 1/35 1/46 0/53 835 R f f34 wat 26m26 1550 0 14.2mg 28.3mg Kurokawa;jnci,71,965-972;1983 kid mix e 13.7mg * P<.0005 + 9.90mg 19.5mg 0/47 28/50 39/49 kid adc e 16.4mg * P<.0005 11.7mg 23.7mg 0/47 21/50 39/49 kid ade e 87.5mg * P<.0005 49.6mg 0/47 8/50 9/49 thy mix e 97.6mg * P<.01 48.2mg 7.87gm 3/52 10/52 12/52 liv mix e no dre P=1. n.s.s. 2/52 1/52 2/52 tba mix e 9.05mg * P<.003 3.96mg 62.6mg 44/52 48/52 52/52 836 R m f34 wat 26m26 1550 0 12.4mg 22.5mg kid mix ev 9.62mg * P<.0005 + 6.93mg 13.9mg 3/53 32/53 46/52 kid adc ev 12.6mg * P<.0005 9.00mg 18.6mg 3/53 24/53 44/52 per mso ev 25.3mg * P<.0005 + 16.1mg 49.8mg 6/53 17/52 28/46 kid ade ev 46.2mg \ P<.0005 22.5mg 0/53 10/53 (5/52) liv mix ev * P<.2 62.8mg n.s.s. 2/53 7/53 6/52 tba mix ev noTD50 P=1. n.s.s. n.s.s. 53/53 53/53 52/52 837 R m f34 wat 52w52 2348m 0 1.00mg 5.00mg 10.0mg 20.0mg DeAngelo;txpy,26,587-594;1998/pers.comm. kid rca ek 16.7mg * P<.04 4.09mg n.s.s. 0/6 0/6 0/6 0/6 2/6 tnv mso ek 36.1mg * P<.5 5.88mg n.s.s. 0/6 0/6 0/6 1/6 0/6 838 R m f34 wat 77w77 2348n 0 1.00mg 5.00mg 10.0mg 20.0mg kid rca ek 15.3mg * P<.003 5.18mg 98.3mg 0/6 0/6 0/6 0/5 4/6 tnv mso ek 15.3mg * P<.003 5.18mg 98.3mg 0/6 0/6 0/6 0/5 4/6 thy mix ek 21.8mg * P<.01 6.53mg 1.32gm 0/6 0/6 0/6 0/5 3/6 thy fcc ek 34.8mg * P<.04 8.51mg n.s.s. 0/6 0/6 0/6 0/5 2/6 839 R m f34 wat 23m23 2348o : 0 1.00mg 5.00mg 10.0mg 20.0mg tnv mso as 11.1mg Z P<.0005 + 7.49mg 17.8mg 0/47 4/49 5/48 9/47 27/43 kid mix as 20.8mg Z P<.0005 + 11.8mg 45.6mg 1/45 1/41 6/45 3/38 12/31 thy mix as 22.2mg Z P<.0005 + 12.2mg 52.2mg 0/36 4/38 1/42 4/36 14/30 kid rca as 31.1mg Z P<.0005 15.7mg 87.6mg 1/45 1/41 4/45 2/38 9/31 thy fca as 35.2mg Z P<.0005 17.4mg 0/36 2/38 1/42 2/36 8/30 kid rcc as 62.2mg * P<.0005 25.6mg 0/45 0/41 2/45 1/38 4/31 thy fcc as 62.9mg * P<.002 25.7mg 0/36 2/38 0/42 2/36 6/30 840 R m f3d wat 6m24 1814m 0 6.25mg Kurokawa;gann,78,358-364;1987/1986a kid ade e 6.67mg P<.0005 3.08mg 18.8mg 0/19 9/19 kid mix e 6.67mg P<.0005 + 3.08mg 18.8mg 0/19 9/19 per mso e 7.84mg P<.0005 3.50mg 24.7mg 0/19 8/19 thy fct e 11.3mg P<.003 4.57mg 58.1mg 0/19 6/19 kid adc e 79.2mg P<.3 12.9mg n.s.s. 0/19 1/19 841 R m f3d wat 9m24 1814n 0 9.38mg kid mix e 4.81mg P<.0005 + 2.42mg 10.9mg 0/19 14/19 kid ade e 5.57mg P<.0005 2.79mg 12.9mg 0/19 13/19 per mso e 14.0mg P<.002 5.97mg 52.5mg 0/19 7/19 kid adc e 16.9mg P<.003 6.85mg 87.2mg 0/19 6/19 842 R m f3d wat 12m24 1814o 0 12.5mg kid mix e 8.32mg P<.0005 + 3.72mg 23.3mg 0/19 9/14 kid ade e 10.1mg P<.0005 4.41mg 30.2mg 0/19 8/14 per mso e 19.4mg P<.003 7.26mg 0/19 5/14 thy fct e 19.4mg P<.003 7.26mg 0/19 5/14 kid adc e 35.5mg P<.02 10.7mg n.s.s. 0/19 3/14 843 R m f3d wat 52w52 1814r 0 25.0mg Kurokawa;gann,78,358-364;1987/19186a kid ade e 4.98mg P<.002 2.66mg 14.9mg 0/8 15/26 per mso e 25.6mg P<.2 8.84mg n.s.s. 0/8 4/26 844 R m f3d wat 24m24 1814s 0 25.0mg Kurokawa;gann,78,358-364;1987/1986a per mso e 12.4mg P<.0005 6.33mg 27.2mg 0/19 15/20 kid mix e 28.7mg P<.0005 + 13.3mg 81.8mg 0/19 9/20 thy fct e 39.8mg P<.002 17.0mg 0/19 7/20 kid ade e 48.0mg P<.004 19.4mg 0/19 6/20 thy fca e 59.5mg P<.008 22.5mg 0/19 5/20 kid adc e P<.04 31.8mg n.s.s. 0/19 3/20 845 R m f3d wat 24m24 1851 0 .750mg 1.50mg 3.00mg 6.25mg 12.5mg 25.0mg Kurokawa;jnci,77,977-982; 1986a/1987 per mso 19.5mg * P<.0005 12.2mg 41.2mg 0/20 0/20 3/20 4/24 2/24 3/20 15/20 kid rct 28.9mg * P<.0005 + 17.0mg 55.2mg 0/20 0/20 0/20 1/24 5/24 5/20 9/20 kid ade 35.7mg * P<.0005 + 20.2mg 78.3mg 0/20 0/20 0/20 1/24 5/24 5/20 6/20 thy fct e 54.7mg * P<.0005 27.4mg 0/16 0/19 0/20 1/24 0/24 3/20 7/19 kid adc * P<.006 67.7mg 2.91gm 0/20 0/20 0/20 0/24 0/24 0/20 3/20 liv nnd 53.2mg Z P<.2 15.2mg n.s.s. 2/20 0/20 4/20 7/24 0/24 6/20 (5/20)

Mutagenicity in Salmonella: positive
SMILES Code for Bromate, potassium: Br(=O)(=O)[O-].[K+]
InChI Code for Bromate, potassium: InChI=1/BrHO3.K/c2-1(3)4;/h(H,2,3,4);/q;+1/p-1
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Bromate, potassium: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (
Last updated: October 3, 2007

PDF documents are best viewed with the free Adobe® Reader
Excel documents are best viewed with the free Excel® Viewer